Inve India ▾

Divi's Laboratories share price & results

Divi's Laboratories Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Among the world's top 3 Active Pharmaceutical Ingredient (API) manufacturers, serving 100+ countries

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue2,974 ₹ crore+26.2% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin42.0 %+10.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit891 ₹ crore+60.0% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity18.78 %+1.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin2.09 %−0.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)16.35 %−6.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 7 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Divi's Laboratories Limited management guidance track record on Inve: 19 targets tracked across analysed earnings calls (3 achieved, 4 missed, 12 open).

TargetOriginal wordingSaidLatest callVerdict
Kakinada Phase 1 Commercial StartAround Q3 FY25Q4 FY24Q1 FY27:Already achieved.
Call transcript, Q1 FY27 · 1 Aug 2026		Achieved
Contrast Media Volume Growth20-30% YoY increase
Call transcript, Q2 FY25 · 9 Nov 2024		Q2 FY25Q1 FY27:Promise remains missed. New updates focus on specific contract commercialization rather than overall volume growth targets.
Call transcript, Q1 FY27 · 1 Aug 2026		Missed
CS Long-Term Agreement CommercializationRevenue impact by Q3 CY2026 / Q4 CY2026 or January 2027
Call transcript, Q4 FY25 · 17 May 2025		Q4 FY25Q1 FY27:Management confirms readiness for regulatory submissions but commercialization remains contingent on approvals, consistent with the previously delayed timeline of 2027.
Call transcript, Q1 FY27 · 1 Aug 2026		Delayed

Source: Inve Guidance Tracker for Divi's Laboratories Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

4 of Divi's Laboratories Limited's 19 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 16 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹9,505.5 +5.03% · +₹455.5

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +44.2% 1Y

₹6.0k₹7.0k₹8.0k₹9.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 12 Nov 2025Q3 FY26 — 11 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 31 Jul 2026

1Y: ₹6,593 on 24 Oct 2025 → ₹9,505.5. High ₹9,624 (23 Sept 2026), low ₹5,821 (6 Apr 2026).

Previous close
₹9,050
Market cap
₹2.5L Cr
52-week range
₹5,821 – ₹9,624
One year
+46.46%
Price to earnings (TTM to Jun 2026)
84.28×
Return on equity (TTM to Jun 2026)
18.78%

Overview

Symbol
NSE:DIVISLAB
Exchange
NSE
Currency
INR

What Divi's Laboratories Limited does

Based on the company's own presentations, annual report and earnings calls.

Divi's Laboratories is an API-exclusive manufacturer that makes generic Active Pharmaceutical Ingredients, provides custom synthesis (contract manufacturing) of APIs and intermediates for global pharmaceutical innovators, and produces nutraceutical ingredients such as carotenoids. It does not market its own dosage forms or compete with its pharma customers, instead acting as a backward-integrated supplier that manufactures most key starting materials in-house to control quality and supply continuity. The company is expanding into newer areas such as peptide APIs (for GLP-1/GLP-2 therapies) and contrast media compounds alongside its core generics and custom synthesis business.

Segments

  • Generic APIs
  • Custom Synthesis
  • Nutraceuticals
Manufacturing facilities
3 (Unit 1 near Hyderabad, Unit 2 at Visakhapatnam, Unit 3 greenfield facility at Kakinada)
Manufacturing capacity
16,550 MT/KL
R&D centers
3 (Sanath Nagar Hyderabad, Choutuppal, Chippada Visakhapatnam)
Scientists across R&D and Process Development/Support Centers
~700
Products across therapeutic areas
~160
Country reach
100+ countries
Founded 1990Headquarters Hyderabad, IndiaEmployees 18,300 (FY 2024-25) Company website

How the price took the results

close before → close after

Q1 FY27
+6.6%
1 Aug
Q4 FY26
−1.9%
23 May
Q3 FY26
+3.4%
11 Feb
Q2 FY26
−0.3%
12 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Divi's Laboratories Limited

Free account: one company. Everything above stays public.

Write why you follow Divi's Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Divi's Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.